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OBJECTIVES This study was designed to assess the prognostic significance of hyperglycemia in acute
myocardial infarction (AMI) in the thrombolytic era using contemporary criteria for
hyperglycemia.
BACKGROUND Most studies that have examined this issue were performed before the widespread use of
disease-modifying therapies and varied in their definition of hyperglycemia, assessment of risk
factors, and reported outcomes.
METHODS There were 1,664 consecutively hospitalized patients with AMI between October 1997 and
October 1998 from a disease-specific, population-based registry. Patients were stratified
according to history of diabetes mellitus and, further, according to whether they had a blood
glucose 198 mg/dl (11 mmol/l). The influences of cardiac risk factors, medications, and
interventions were analyzed, and multivariate logistic regression was used to determine the
influence of blood glucose on mortality.
RESULTS In patients without a history of diabetes, glucose levels were 198 mg/dl in 1,078 patients
(Group 1) and 198 mg/dl in 135 (Group 2). Of those with diabetes, glucose levels were
198 mg/dl in 169 patients (Group 3) and 198 mg/dl in 282 (Group 4). Compared with
Group 1 patients, the odds ratios (95% confidence interval) for in-hospital mortality among
those in Groups 2, 3, and 4 were 2.44 (1.42 to 4.20; p  0.001), 1.87 (1.05 to 3.34; p 
0.035), and 1.91 (1.16 to 3.14; p  0.011), respectively. These groups also had greater
12-month mortality.
CONCLUSIONS Hyperglycemia in AMI is associated with poor outcome even among patients without known
diabetes. This finding underlines the need for aggressive glucose management in this setting
and may support a more vigorous screening strategy for early recognition of diabetes. (J Am
Coll Cardiol 2002;40:1748–54) © 2002 by the American College of Cardiology Foundation
Diabetes mellitus is an established major cardiovascular risk
factor associated with increased prevalence of coronary
artery disease (CAD) (1). Patients with diabetes often have
numerous concomitant cardiac risk factors with a higher
incidence of acute myocardial infarction (AMI) and con-
gestive heart failure (CHF). Poor glycemic control and
insulin resistance are associated with significant endothelial
cell dysfunction, procoagulability, and diffuse multi-vessel
CAD.
Patients either with or without a prior history of diabetes
mellitus may present with hyperglycemia during AMI.
Among patients with no prior history of diabetes, hyper-
glycemia may reflect previously undiagnosed diabetes, pre-
existing carbohydrate intolerance, stress-related carbohy-
drate intolerance, or a combination of these (2). Several
studies have reported an association between elevated blood
glucose upon admission and subsequent increased adverse
events, including CHF, cardiogenic shock, and death (3–
20). However, an overview of these reports (2) was critical of
the varying definitions for hyperglycemia (blood sugars
ranged from 119 mg/dl (6.6 mmol/l) to 200 mg/dl (11.1
mmol/l) and of the sketchy assessment of patient variables,
previous medical therapy, and in-hospital interventions.
Furthermore, many of the studies were conducted in the
pre-thrombolytic era.
Given that the management of diabetes mellitus, other
cardiac risk factors, and AMI has evolved significantly since
the publication of these reports, it is uncertain whether
hyperglycemia upon admission, irrespective of the diagnosis
of diabetes, remains an independent predictor of in-hospital
morbidity and mortality. The objective of this study was to
determine whether the level of blood glucose upon admis-
sion remains associated with adverse in-hospital clinical
outcomes after AMI in the contemporary era, considering
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recent advances in treatment; and we sought to take a
population-based approach toward examining this question.
METHODS
Setting and study population. Nova Scotia is a province of
Canada with a population of approximately 940,000 per-
sons. The clinical implications of elevated blood glucose
upon hospital admission were explored using data from the
Improving Cardiovascular Outcomes in Nova Scotia
(ICONS) project. This is a large, prospective-cohort disease
management study whose rationale and methods have been
comprehensively described elsewhere (21).
Briefly, the ICONS study protocol received ethics review
and approval at the Queen Elizabeth II Health Sciences
Centre in Halifax and at several other institutions across
Nova Scotia. Since October 15, 1997, extensive data have
been compiled through primary chart abstraction on all
Nova Scotia residents consecutively hospitalized in a Nova
Scotia health care facility with, among other conditions,
AMI. Daily patient lists, sorted by admission ward, are
obtained from the admitting or health records departments
at all provincial adult care hospitals. These are scanned, and
charts are requested on patients who might be having an
AMI. Similarly, lists of patients sorted by discharge diag-
nosis (ICD-9-CM codes 410–414) are obtained from
health records departments. All diagnosis types (including
most responsible diagnosis, primary diagnosis, secondary
diagnoses, and complications) are requested, and charts are
reviewed. This process ensures high sensitivity for identify-
ing all patients with a clinical diagnosis of AMI. The
ICONS investigators defined cases on the basis of clinical
diagnosis, as opposed to specific electrocardiographic and
enzymatic criteria for two reasons: first, to enable compar-
isons with published reports using administrative data sets,
and second, to avoid missing events in an era when more
sensitive enzyme markers of myocardial injury are redefining
case definition (22). For the present study, information was
collected pertaining to the 12-month interval between
October 15, 1997, and October 14, 1998, which was the
baseline phase of the parent study.
Data collection. Specially trained nurses and medical
record technologists abstracted detailed information from
each inpatient chart, including documentation of modifiable
cardiac risk factors, particularly diabetes. Data were also
collected pertaining to comorbid illnesses, admission med-
ications, the results of investigations (including the first
blood glucose upon admission), processes of care in the
hospital, and outcomes. The outcomes of interest included
in-hospital mortality as determined from chart review, and
one-year mortality obtained through record linkage to the
Nova Scotia Vital Statistics Registry.
Data quality control. Data collection for the ICONS
study commenced only after an accuracy level of at least 95%
for data abstraction was achieved. This required the imple-
mentation of several quality control mechanisms, described
elsewhere (21), including random reabstraction of charts,
software logic checks built around key fields, and periodic
review of a random sample of entered cases.
The death registration process in Nova Scotia involves
numerous quality checks, including upon completion of
death registration by division registrars, at input into the
computer registration system, as a “pending” file, at file
“completion,” and before microfilming. Data sent to Statis-
tics Canada are assigned an ICD code via machine coding,
enhancing consistency at a national level. Coded data
returned to Nova Scotia are rechecked and rematched with
provincial data, including against such clinical registries as
the one maintained by Cancer Care Nova Scotia. Nova
Scotia Vital Statistics sends periodic database information,
corrections, updates, and queries to Statistics Canada for
further verification. Although all these steps ensure a high
degree of data accuracy, ICONS study research staff addi-
tionally screen the obituary sections of provincial newspa-
pers and continuously monitor those patients enrolled for
longitudinal out-of-hospital follow-up in the parent study
(about 50% of the total hospitalized).
Data analysis. Although it is not the preferred method,
carbohydrate intolerance can be diagnosed on the basis of
two consecutive elevated blood sugars and associated symp-
toms (23). Consequently, hyperglycemia was defined in the
current study as a random blood glucose at admission that
was 198 mg/dl (11 mmol/l) as per the 2002 and 1998
guidelines of the American and Canadian Diabetic Associ-
ations, respectively (23,24). Patients were stratified into four
groups, based on their history of diabetes mellitus and the
blood glucose level at admission:
Group 1: No previous diagnosis of diabetes and random
blood sugar 198 mg/dl;
Group 2: No previous diagnosis of diabetes and random
blood sugar 198 mg/dl;
Group 3: Known diabetes and random blood sugar198
mg/dl;
Group 4: Known diabetes and random blood sugar198
mg/dl.
This is an observational study, and the data are reported
using simple descriptive statistics. The chi-squared test was
used to assess differences in the distribution of categorical
variables; t tests or analysis of variance were used to compare
continuous variables. Multivariate analysis was performed
using stepwise logistic regression in order to identify inde-
pendent predictors of in-hospital mortality. A significance
Abbreviations and Acronyms
AMI  acute myocardial infarction
CAD  coronary artery disease
CHF  congestive heart failure
ICONS  Improving Cardiovascular Outcomes in Nova
Scotia
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level of p  0.2 in univariate analysis was specified for
maintaining variables in the multivariate model. Only those
variables that remained significant at p 0.05 were retained
in the final model. The strength of association of glycemic
status was assessed by comparison of the three groups with
a disordered blood glucose profile to the “normal” (Group 1)
patients not previously diagnosed with diabetes and with a
random blood sugar 198 mg/dl.
RESULTS
There were 1,664 patients hospitalized with AMI in Nova
Scotia during the 12 months of interest: 1,103 (66.3%) with
non–ST-segment elevation AMI and 561 (33.7%) with
ST-segment elevation AMI or left bundle branch block.
In-hospital mortality rates were 12.9% for patients with
non–ST-segment elevation AMI and 10.9% for those with
ST-segment elevation AMI or left bundle branch block,
whereas cumulative mortality at one year was 18.1% and
13.3%, respectively.
The majority of patients (72.9%) did not have a history of
diabetes. The reference (Group 1) cohort made up 64.8% of
the overall population. Patients who were not previously
known to have diabetes but who were hyperglycemic upon
admission made up 8.1% of the total. Patients with known
diabetes and with normal blood glucose upon presentation
represented 10.2%, whereas diabetic patients whose blood
glucose levels exceeded 198 mg/dl contributed the remain-
ing 16.9%.
Patient characteristics stratified by the four study sub-
groups are shown in Table 1. Patients known to have
diabetes were significantly older than “normals,” yet the
oldest group of patients had hyperglycemia but no known
history of diabetes. Males made up almost 70% of the
normal-glucose non-diabetic group, but only half of the
non-diabetic hyperglycemic group. Predictably, creatinine
was higher in both diabetic cohorts by comparison to
“normals,” but the highest creatinine levels were seen in
hyperglycemic patients not previously known to have dia-
betes. Other major cardiac risk factors had a varied distri-
bution across groups, and those with known diabetes were
most likely to have sustained a previous myocardial infarc-
tion independent of glucose level. However, a prior history
of CHF was most common among the patients with
abnormally elevated admission blood sugars independent of
diabetic status.
Admission medications are shown in Table 2. In general,
patients with diabetes were most likely to be receiving
efficacious, cardiovascular disease-modifying drugs such as
Table 1. Patient Characteristics According to Diagnosis of Diabetes and Glycemic Status
Variable
Group 1*
(n  1,078)
Group 2†
(n  135)
Group 3‡
(n  169)
Group 4§
(n  282) p Value
Age (yrs) 64.7 69.9 68.6 68.2  0.0001
Male (%) 68.5 51.1 62.7 56.7  0.0001
Glucose (mmol/l) 7.3 21.0 8.6 19.0  0.0001
Creatinine (mmol/l) 110.5 133.8 125.7 125.8 0.0001
Smoker (%) 64.8 52.6 60.9 57.5 0.0112
Hypertension (%) 45.1 49.6 63.3 64.5  0.0001
Hyperlipidemia (%) 33.3 23.7 44.4 36.9 0.0013
Prior myocardial infarction (%) 24.2 25.9 34.3 33.0 0.0028
Prior heart failure (%) 6.9 18.5 17.2 19.5  0.0001
Peripheral vascular disease (%) 3.1 0.7 5.9 4.3 0.0647
*Group 1  No previous diagnosis of diabetes and random blood glucose 198 mg/dl (11 mmol/l). †Group 2  No previous
diagnosis of diabetes and random blood glucose 198 mg/dl. ‡Group 3  Known diabetes and random blood glucose 198
mg/dl. §Group 4  Known diabetes and random blood glucose 198 mg/dl.
Table 2. Admission Medication According to Diagnosis of Diabetes and Glycemic Status
Admission Medication
Group 1*
(n  1,078)
Group 2†
(n  135)
Group 3‡
(n  169)
Group 4§
(n  282) p Value
Oral hypoglycemic (%) 0 0 50.3 62.8  0.0001
Insulin (%) 0 0 20.7 27.7  0.0001
Aspirin (%) 31.1 25.2 33.1 35.1 0.2128
ACEI (%) 18.9 23.0 30.8 34.8  0.0001
ARB (%) 1.9 0 2.4 4.6 0.0145
Beta-blocker (%) 31.1 25.2 41.4 37.2 0.0042
CCB (%) 5.1 10.4 14.8 9.9  0.0001
HMG CoA (%) 15.1 5.2 17.8 16.0 0.0093
Nitrates (%) 21.6 26.7 30.2 34.8  0.0001
Digoxin (%) 3.4 6.7 7.1 7.1 0.0126
*Group 1  No previous diagnosis of diabetes and random blood glucose 198 mg/dl (11 mmol/L). †Group 2  No previous
diagnosis of diabetes and random blood glucose 198 mg/dl. ‡Group 3  Known diabetes and random blood glucose 198
mg/dl. §Group 4  Known diabetes and random blood glucose 198 mg/dl.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; CCB  calcium channel blocker;
HMG CoA  hydroxymethylglutaryl-coenzyme A reductase inhibitor.
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aspirin, beta-blockers, angiotensin-converting enzyme in-
hibitors, and hydroxymethylglutaryl-coenzyme A reductase
inhibitors. By contrast, patients who were hyperglycemic
with no previous history of diabetes tended to have the
lowest rates of these therapies upon presentation.
Differences were noted across groups in terms of their
hospital course (Table 3). The “normal” group had a greater
propensity to receive thrombolytic therapy, possibly because
ST-segment elevation or left bundle branch block was more
commonly seen on their admission electrocardiograms.
These patients were most likely to undergo percutaneous
coronary intervention in the hospital, whereas patients with
diabetes were least likely to receive this therapy. However,
there was no difference in the rate of in-hospital bypass
surgery across groups. Length of hospital stay tended to be
longer for patients with diabetes compared to those without,
although this difference was of only marginal significance.
Rates of heart failure during the index hospitalization were
similar across the hyperglycemic cohorts and in each in-
stance were about double those documented in the corre-
sponding euglycemic groups.
Multivariate analysis identified several variables that were
independently associated with in-hospital mortality (Table
4). Diabetic status, irrespective of glucose level upon admis-
sion, was a predictor of adverse outcome; but patients with
hyperglycemia and no history of diabetes had an even worse
outcome, with more than a twofold higher risk. Patients
known to have diabetes and those with hyperglycemia
without a history of diabetes continued to suffer a relatively
worse outcome even up to one year (Fig. 1). Variables
associated with lower in-hospital mortality include exposure
to disease-modifying drugs known to be associated with
long-term benefit.
To assess whether it was blood sugar alone or, alterna-
tively, hyperglycemia as part of a metabolic syndrome that
was associated with adverse outcome, multivariate analysis
was repeated first with body mass index and then with
individual lipid levels included as additional variables.
Height and weight information was available for 916
patients (55%), and these were stratified into three groups of
body mass index based on World Health Organization
criteria with 18.5 to 24.9 kg/m2, 25 to 29.9 kg/m2, and30
kg/m2 representing normal, overweight, and obese individ-
uals, respectively. In the resulting model, body mass index
was not linked with outcome, although the three groups
with deranged glucose profiles (Groups 2 to 4) continued to
be independently associated with prognosis. Total choles-
terol/high density lipoprotein cholesterol ratio, low-density
lipoprotein cholesterol, and triglyceride levels were also
considered, but neither these variables nor a history of
hyperlipidemia correlated independently with outcome.
DISCUSSION
Our study suggests that patients presenting with an AMI
who are hyperglycemic upon admission represent a high-
risk population. The worst outcomes occurred among those
without a prior history of diabetes. This may relate to
hyperglycemia being associated with several high-risk fea-
tures, including older age, female gender, and a prior history
of CHF. However, an elevated blood sugar upon admission
was correlated with more in-hospital CHF and greater
in-hospital and one-year mortality independent of a history
Table 3. Admission Electrocardiogram and Course in Hospital According to Diagnosis of
Diabetes and Glycemic Status
Variable
Group 1*
(n  1,078)
Group 2†
(n  135)
Group 3‡
(n  169)
Group 4§
(n  282) p Value
STEMI/LBBB (%) 36.0 30.4 25.4 31.6 0.0301
Thrombolysis (%) 36.7 30.4 28.4 26.6 0.0035
Heart failure (%) 13.3 32.6 18.9 35.5  0.0001
PCI (%) 11.9 8.2 6.5 5.7 0.0049
CABG (%) 4.1 4.4 4.7 5.3 0.8319
Mean length of stay (days) 10 11 13 12 0.0465
*Group 1  No previous diagnosis of diabetes and random blood glucose 198 mg/dl (11 mmol/l). †Group 2  No previous
diagnosis of diabetes and random blood glucose 198 mg/dl. ‡Group 3  Known diabetes and random blood glucose 198
mg/dl. §Group 4  Known diabetes and random blood glucose 198 mg/dl.
CABG  coronary artery bypass grafting; PCI  percutaneous coronary intervention; STEMI/LBBB  ST-elevation
myocardial infarction/left bundle branch block.
Table 4. Independent Predictors of Outcome
Variable Odds Ratio 95% CI p Value
Group 1* 1.00 — —
Group 2† 2.44 1.42–4.20 0.0013
Group 3‡ 1.87 1.05–3.34 0.0346
Group 4§ 1.91 1.16–3.14 0.0105
Peripheral vascular disease 4.33 1.88–9.96 0.0006
Insulin on admission 2.05 1.07–3.92 0.0299
Age (per 10 years) 1.89 1.58–2.24  0.0001
Prior heart failure 1.81 1.09–3.00 0.0219
Prior myocardial infarction 1.95 1.28–2.98 0.0020
Female 1.66 1.31–2.43 0.0096
Creatinine (per 10 mmol/l) 1.04 1.02–1.05 0.0001
Aspirin on admission 0.53 0.33–0.86 0.0101
ACEI on admission 0.46 0.26–0.79 0.0052
Beta blocker on admission 0.25 0.14–0.44  0.0001
Digoxin on admission 0.13 0.04–0.47 0.0018
HMG CoA on admission 0.06 0.01–0.46 0.0067
*Group 1  No previous diagnosis of diabetes and random blood glucose 198
mg/dl (11 mmol/l). †Group 2 No previous diagnosis of diabetes and random blood
glucose 198 mg/dl. ‡Group 3  Known diabetes and random blood glucose 198
mg/dl. §Group 4  Known diabetes and random blood glucose 198 mg/dl.
ACEI  Angiotensin-converting enzyme inhibitor; CI  confidence interval;
HMG CoA  hydroxymethylglutaryl-coenzyme A reductase inhibitor.
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of diabetes mellitus or of any of the high-risk features listed
earlier. Furthermore, hyperglycemia conferred risk indepen-
dent of body mass index or history of hyperlipidemia,
suggesting that glucose status itself may be contributing to,
or is a key marker of, adverse outcome.
Hyperglycemia and unrecognized diabetes mellitus. Hy-
perglycemia in non-diabetic patients most likely represents
undiagnosed diabetes. In Canada, the incidence of known
diabetes is 5%, but it has been estimated that at least another
5% of the population has this condition yet remains undi-
agnosed (24). The 8.1% incidence of hyperglycemia seen in
the present study among patients hospitalized with AMI
and not known to have diabetes is consistent with the
published estimates and the hypothesis that many of these
individuals have unrecognized diabetes.
Although several reports have equated acute hyperglyce-
mia with glucose intolerance or frank diabetes mellitus, this
has not been a universal finding, and clarification has been
limited by differing definitions of hyperglycemia (19,25–27).
Even if the hyperglycemic “non-diabetic” population did
represent individuals with undiagnosed diabetes, their rela-
tively worse outcomes vis-a`-vis diagnosed diabetic patients
still warrant an explanation. It is likely that such individuals
are in fact undiagnosed and hence untreated diabetic pa-
tients, with potentially many years of uncontrolled elevated
blood sugar resulting in increased endothelial damage and
thus greater risk for macro- and micro-vascular morbidity.
Overt diabetes likely represents one end of the spectrum of
carbohydrate intolerance and increasing cardiovascular risk
(28). However, whereas recognized diabetics with vigorous
glycemic control may be to some extent protected against
the additional metabolic stresses associated with AMI,
diabetic patients who are undertreated do poorly and fare
better only by comparison with those patients who, by virtue
of their undiagnosed state, are receiving no diabetic therapy
whatsoever.
Stress hyperglycemia. It is unclear whether so-called stress
hyperglycemia predisposes to a worse outcome or is simply
a marker of poor prognosis. Though inconclusive, studies
suggest that stress hyperglycemia may be a marker of
extensive myocardial damage (29). Better established
through both in-vitro and in-vivo studies is the fact that an
elevated blood glucose level, whether acute or chronic,
adversely affects endothelium-dependent vasodilation and
impairs macrophage and lymphocyte function (30–32).
Hyperglycemia during AMI may reflect a compromised
metabolic state and is associated with a surge of serum
catecholamines and decreased insulin sensitivity that in-
creases the turnover of potentially harmful free fatty acids
(13). As well, hyperglycemia may promote an osmotic
diuresis, leading to a reduced circulating volume and de-
creased end-diastolic and stroke volumes through interfer-
ence with the Frank-Starling mechanism of myocardial
contractility (33,34).
If stress hyperglycemia indeed reflects an underlying
dysglycemic state, then this would be expected to correlate
with a higher overall risk for more extensive CAD and
would explain a worse prognosis after AMI (35). Thus,
elevated plasma glucose would both reflect the acute stress
and predict an increased propensity for long-term cardio-
vascular events (2). Prior studies have shown that an
elevated admission blood glucose in AMI correlates with an
increased incidence of CHF, cardiogenic shock, and in-
hospital mortality (7,11,12,36). In contrast, the utility of
hemoglobin A1C in predicting adverse outcomes in the
setting of AMI remains uncertain, considering the varying
results of studies (7,36,37).
Hyperglycemia as a trigger for more aggressive manage-
ment. If hyperglycemia predicts adverse events, then iden-
tifying it and the metabolic milieu from which it arose, as
well as managing these, might be expected to attenuate risk
in both the short and long term. Malmberg and associates
Figure 1. Mortality in the hospital and from discharge to one year, by diabetes and glycemic status. Group 1: no previous diagnosis of diabetes and random
blood glucose 198 mg/dl (11 mmol/l); Group 2: no previous diagnosis of diabetes and random blood glucose 198 mg/dl; Group 3: known diabetes and
random blood glucose 198 mg/dl; Group 4: known diabetes and random blood glucose 198 mg/dl.
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(38,39) showed that the use of insulin-glucose therapy in
hyperglycemic AMI patients resulted in a 30% relative risk
reduction in one-year mortality. However, there was no
demonstrable short-term benefit, with in-hospital survival
being similar in treatment and control groups. Several
questions are raised by these results, including whether there
are high-risk patient subgroups that could benefit in the
short term with intensive insulin-glucose therapy or
whether comparable long-term benefit could be achieved
through the use of insulin in non-diabetic patients (38,39).
Many of the variables independently associated with adverse
outcome in our study, including peripheral vascular disease,
increasing age, previous AMI, previous CHF, renal insuf-
ficiency, and insulin upon admission, can reflect significant
systemic atherosclerosis, decreased myocardial reserve, and
preceding metabolic abnormality. Patients at highest risk for
both in-hospital and 12-month mortality were those with
prior AMI, heart failure, and increased age. Yet, although
high-risk patients can generally expect to derive more
benefit from aggressive treatment, there is insufficient evi-
dence to support the use of insulin-glucose infusion therapy
in all patients, regardless of admission blood glucose (40–
42).
Study limitations. This study is observational and non-
randomized. However, it does reflect the “real world”
population in that it includes all consecutive patients hos-
pitalized with AMI in a self-contained health care system
and thus provides important insights into the treatment and
outcomes of such patients when stratified according to their
glycemic status. We could not determine the true incidence
of diabetes mellitus, especially among persons without a
prior history of this condition. However, an admission
diagnosis of diabetes probably has high specificity, consid-
ering that any individuals declaring this condition very likely
had it. Because hemoglobin A1C levels are not routinely
measured in patients with AMI, we are unable to comment
on the impact of chronically impaired glucose control in our
study population. Finally, no attempt was made to analyze
sequential glucose levels in the hospital, and thus we have no
information on the outcome of patients who may have
developed hyperglycemia later in their hospital course.
However, studies such as that of Malmberg et al. (39) have
determined the efficacy of aggressive glucose management
on the basis of admission blood glucose.
Conclusions. Independent of diabetic status, the occur-
rence of hyperglycemia during AMI is associated with a
sub-population of patients at particularly high risk for an
adverse clinical outcome. In general, these patients are older,
have multiple cardiac risk factors, and are more likely to
have a prior history of CHF. Even with the highly effica-
cious treatment strategies currently available, persons pre-
senting with AMI and hyperglycemia are at increased risk
for CHF or death in hospital; all-cause mortality at one year
is also higher.
At the time of diagnosis, patients with diabetes have an
increased prevalence of micro- and macro-vascular compli-
cations regardless of symptoms. Expert consensus recom-
mends screening of all asymptomatic individuals beginning
at age 45 (23,24), although there is controversy over the
cost-effectiveness of this approach (23,43). Even though
Tuomilehto et al. (44) demonstrated the beneficial effect of
lifestyle modification on the incidence of type 2 diabetes in
patients at high risk, it is uncertain whether earlier diagnosis
and additional years of treatment result in fewer diabetes-
related events. However, the poor cardiovascular outcomes
of hyperglycemic patients in our study, particularly among
those not previously known to be diabetic, lend support for
aggressive screening strategies aimed at the early recognition
of diabetes.
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